Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

This national clinical trial aims to identify treatments that may be beneficial for adults hospitalised with confirmed COVID-19

Peter Horby, Professor of Emerging Infectious Diseases and Global Health

A range of potential treatments have been suggested for COVID-19 but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive. The RECOVERY Trial will begin by testing some of these suggested treatments: 

  • Lopinavir-Ritonavir (commonly used to treat HIV)
  • Low-dose Dexamethasone (a type of steroid, which is used in a range of conditions typically to reduce inflammation).
  • Hydroxychloroquine (related to an anti-malarial drug)
  • Inhaled interferon-beta1a (an antiviral drug; not currently in use in this trial)

Data from the trial will be regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. The RECOVERY Trial team will constantly review information on new drugs and include promising ones in the trial.

Letter from the Chief Medical Officers

The Chief Medical Officers of England, Wales, Scotland and Northern Ireland, and the NHS Medical Director, have written a letter to all doctors strongly encouraging participation in the national randomised trials in COVID-19 of which RECOVERY is one. Please click on the link below to read the letter and pass it on to your colleagues.

The importance of COVID-19 clinical trials

The RECOVERY Trial is registered at ISRCTN50189673 
EU Clinical Trials Register: EudraCT 2020-001113-21